bluebird bio, Inc . (Nasdaq: BLUE) today announced that the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded based on the review of all available data that the benefit-risk balance of medicinal products containing ZYNTEGLO™ (betibeglogene autotemcel gene therapy) remains favorable. Read More
This week’s announcement includes a step to the side for CMO Amit Rakhit, who will transition to the…
Hyperfine, Inc., Creator of the First FDA-Cleared Portable MRI Device, and Liminal Sciences, Inc. To Be Listed on Nasdaq Through a Business Combination With HealthCor Catalio Acquisition Corp.
Hyperfine today announced their entry into a definitive business combination agreement with HealthCor Catalio Acquisition Corp. Read More
Alzheimer’s Drug Discovery Foundation (ADDF) Investment Boosts Search for Digital Biomarkers for Early Alzheimer’s
The Alzheimer’s Drug Discovery Foundation has announced up to $2 million of funding for a collaborative research initiative…